CTOs on the Move

Health Education Alliance

www.heaemail.com

 
Health Education Alliance is a White Plains, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.heaemail.com
  • 445 Hamilton Ave Ste 605
    White Plains, NY USA 10601
  • Phone: 914.948.9393

Executives

Name Title Contact Details

Similar Companies

D F G Inc

D F G Inc is a Ogden, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Grace Davison Discovery Sciences

Grace Davison Discovery Sciences is a Deerfield, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sunshine Care Partners

SunshineCare provides you guidance through medical, case management, and community services as your advocate. Our goal is to enhance your quality of life and to provide a comprehensive approach you the quality of healthcare for you and your loved one as you live with chronic illness. We work hand in hand with your existing physicians individual plan of care.

Health Council Canada

Health Council Canada is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Accord BioPharma

Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.